Earnings Call · Q3 FY2022·2022-11-13

Q3 22EPS +6.12%·Rev n/aQ2 22EPS -10.71%·Rev n/aQ1 22EPS -34.78%·Rev n/aQ4 21EPS -100.00%*·Rev n/a⚠ consensus missing

Amylyx Pharmaceuticals, Inc. AMLX

Lindsey Allen — Investor Relations or Corporate Communications (inferred from call introduction)

Justin Klee — Co-CEO

Margaret Olinger — Chief Commercial Officer

James Frates — Chief Financial Officer

Josh Cohen — Co-CEO

−3.9%1d on move date−4.9% vs SPY3d+0.1%5d−1.9%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AMLX calls or request research access.

More AMLX calls Browse calls Request research access